Core Viewpoint - The CDC has issued a directive to end all research projects involving the use of monkeys by the end of this year, marking a significant shift in animal research policy in the U.S. [3][4] Group 1: CDC Directive and Its Implications - The directive affects approximately 200 monkeys used primarily for infectious disease research, including HIV prevention and antiviral treatments [3]. - This is the first time a U.S. government agency has terminated non-human primate research since the NIH initiated a retirement plan for chimpanzees a decade ago [3]. - The future of these monkeys is uncertain, with possibilities including relocation to primate sanctuaries or euthanasia [3]. Group 2: New Methodologies in Research - Advocates for "new methodologies" such as organoids believe this marks the beginning of a "post-animal era" in research [3]. - The CDC's directive is seen as a potential model for transitioning to advanced alternative technologies, although achieving complete replacement of animal models is complex [4]. - The NIH still oversees nearly 7,000 non-human primates, indicating that the CDC's directive does not apply to all research institutions [4]. Group 3: Challenges of Replacement Technologies - Experts caution that while organoids and other new methodologies show promise, they cannot fully replicate the complexity of human diseases [4]. - The current state of recognized alternatives to animal testing remains limited, with few validated methods available [4]. - The debate continues on the extent to which organoids can replace animal models in biomedical research [4]. Group 4: Global Perspective and Future Directions - The focus should be on which countries can effectively implement alternative methodologies in translational medicine and drug evaluation [5]. - The CDC's decision highlights a growing contradiction in biomedical research: the need for new therapies while still relying on animal models for certain critical research areas [5]. - Addressing the balance between ethical considerations and scientific needs is essential for the advancement of both science and ethics [5].

目前这些猴子的前途未卜，其中一部分可能被转移到灵长类动物保护区，另一部分可能会被安乐死。 近日，一篇刊登在《科学》（Science）网站的消息披露，美国大量的实验用猴将被迫"退休"。 消息称，美国疾病控制与预防中心（CDC）内部已发出指令：要求在今年年底前结束所有使用猴子实 验的研究项目。根据《科学》网站的消息，受影响的是CDC在亚特兰大的几处设施，涉及大约两百只 猕猴和近缘物种，这些猴子主要用于传染病相关研究，比如HIV暴露前预防、抗病毒制剂、肝炎等。 这是继10年前美国国立卫生研究院（NIH）启动实验用黑猩猩"退休"计划以来，美国政府机构首次终止 非人灵长类动物研究项目。目前这些猴子的前途未卜，其中一部分可能被转移到灵长类动物保护区，另 一部分可能会被安乐死。 消息一传出，一些网站就开始大量转发，尤其是一些所谓的"类器官"（organoid）平台的倡导者，他们 认为科研"新方法学"的号角已经吹响，"后动物时代"即将到来。 自美国总统特朗普上任以来，包括美国食品药品监督管理局、环境保护署和NIH在内的几家机构负责人 均已宣布，计划减少对动物实验的依赖，并打算在器官芯片及其他"新方法学"研究方面投入更多资金。 ...

Core Viewpoint - The article discusses the advancements in organoid technology, particularly the development of a single-chain antibody (scTS2/16) that enhances organoid growth in defined matrices, paving the way for standardized and clinically applicable organoid cultures [3][19]. Group 1: Organoid Technology Overview - Organoids are miniaturized, self-organizing tissue models that can be cultured in vitro, providing powerful tools for drug development, precision medicine, and regenerative medicine [2]. - The reliance on Matrigel, a mouse-derived matrix, poses significant limitations due to its unclear chemical composition and batch-to-batch variability, hindering the translational application of organoids [2][6]. Group 2: Research Breakthrough - A study published by Hans Clevers in Nature Biotechnology introduced scTS2/16, a single-chain derivative of an integrin-activating antibody that significantly enhances organoid growth in both Matrigel and collagen hydrogels [3]. - The research indicates that scTS2/16 can increase the yield of gastrointestinal organoids by up to 5 times in traditional matrices and 6-7 times in defined collagen hydrogels [14]. Group 3: Mechanism of Action - The mechanism behind scTS2/16's effectiveness lies in its ability to maintain integrin β1 in an active state, enhancing the interaction between cells and the extracellular matrix [16][17]. - The study confirmed that scTS2/16 specifically enhances the interaction between integrins and collagen, facilitating better organoid growth [17]. Group 4: Clinical Application Potential - The research highlights the potential for scTS2/16 to be used in clinical applications due to its controllable quality and compatibility with existing clinical-grade collagen products [19]. - The versatility of scTS2/16 allows for its use in both 3D hydrogel cultures and 2D platforms, making it suitable for high-throughput drug screening [19].

Group 1 - QYResearch is recognized for its authoritative industry analysis and customized reports, widely cited by numerous well-known domestic and international companies, securities firms, and media [1] - The ASIC design service market in China is projected to generate sales revenue of $1.503 billion in 2023, with expectations to reach $3.416 billion by 2030 [2] - The global servo system market is estimated to be $15.611 billion in 2023, with a compound annual growth rate (CAGR) of 4.73%, reaching $20.604 billion by 2029 [5] Group 2 - The global vehicle dashboard market is dominated by a leading domestic company, ranked first in China and eighth globally, according to QYResearch [7] - The global humidifier market is expected to grow at a CAGR of over 10% in the next five years, with integrated and smart products taking a leading position [10] - The market for osmotic laxatives in China is projected to exceed 7.313 billion yuan by 2029, capturing 33.65% of the total constipation medication market [12] Group 3 - The global high-speed connector market is anticipated to reach $21.6 billion by 2030, providing significant expansion opportunities for suppliers [15] - The directional drilling tools market is expected to exceed $9.42 billion in 2024 and surpass $26.88 billion by 2037, with a CAGR of over 8.4% [17] - The global optical switch market is projected to reach $2.02 billion by 2031, with a CAGR of 16.3% [20] Group 4 - The global semiconductor robot market is currently dominated by foreign manufacturers, holding over 90% of the market share in China [22] - The global automatic wafer testing probe market is estimated to be around $1.156 billion in 2024, characterized by high market concentration [24] - The global emergency kit market is expected to reach $1.061 billion by 2031, with a CAGR of approximately 7.3% [27] Group 5 - The global home wireless router market is projected to grow at a CAGR of 5.8% from 2025 to 2031 [29] - The global medical device market is expected to reach $635.8 billion by 2024 [32] - The global SD-WAN market is estimated to reach $51.8 billion by 2031, with a CAGR of 32.6% [35] Group 6 - The global organ-on-a-chip market is expected to grow at a CAGR of 31.2% from 2024 to 2030 [69] - The global automotive drive motor core market is projected to reach $4.678 billion by 2030, with a CAGR of 11.85% [62] - The global eSIM card market is entering a rapid expansion phase, particularly in the IoT and consumer electronics sectors [65]

Core Insights - The rapid advancements in biomedical engineering are reshaping the future of human health, with innovations such as 3D bioprinting of organs and tissues becoming increasingly feasible [3][20] - Significant breakthroughs include the successful cultivation of a living heart organoid and the discovery of a molecular switch for organ regeneration in mammals [1][4] Group 1: Innovations in Biomedical Engineering - The first living heart organoid over 1 cm in diameter was successfully cultivated in Shanghai, offering new hope for organ transplantation [1][4] - Researchers have developed a method to 3D print active organoids using bioprinting technology, which can replicate the structure and function of real organs [4][20] - The production of bioprinting materials involves creating billions of living cells, which are cultivated in specialized environments to ensure rapid and large-scale expansion [6][8] Group 2: Applications of Bioprinting - Bioprinting technology is being utilized for drug testing, allowing for the creation of mini-tumor models that can simulate patient responses to various treatments [16][18] - The development of in-situ printing techniques enables the direct repair of damaged tissues within the body, such as printing new skin or heart patches [18][20] Group 3: Cross-Disciplinary Collaborations - Collaborative efforts among multiple research institutions have led to the creation of a novel visual prosthetic that allows blind animals to perceive infrared light, showcasing the potential of interdisciplinary research in biomedical engineering [21][27] - The integration of nanomaterials and advanced engineering techniques has resulted in significant improvements in the functionality and efficiency of bioelectronic devices [25][27] Group 4: Strategic Development in Life Sciences - The Chinese government is prioritizing life sciences in its strategic development plans, with initiatives aimed at accelerating the commercialization of cutting-edge technologies in cell and gene therapy [28] - Cities like Shanghai and Shenzhen are actively fostering innovation ecosystems around organoids and biomanufacturing, with ambitious targets for the growth of the biopharmaceutical industry [28]

OTC2025： 产学研医共促类器官技术突破 类器官技术正在快速发展，并逐步进入临床试验阶段。虽然仍面临挑战，但随着生物工程、人工智能和细 胞培养技术的进步，类器官有望成为精准医疗和再生医学的核心工具，为人类健康带来革命性突破。值此 之际， OTC2025 类器官前沿应用与 3D 培养论坛 重磅来袭：围绕 类器官与疾病建模、 3D 细胞培养、 AI+ 器官芯片推进新药研发、类器官培养及质量控制 等角度展开深度探讨。 论坛名称 ： OTC2025 类器官前沿应用与 3D 培养论坛 02 为何举办OTC2025 1 利用 AI 分析类器官大规模数据 ，加速个性化药物筛选疾病建模； 2 开发 自动化培养系统 ，提高类器官生产效率，降低成本； 3 结合 3D 生物打印和微流控技术，增加类器官的细胞类型和结构复杂度，以更好地模拟人体微环境； 4 研究如何引入血管系统和免疫细胞，增强类器官的功能性； 5 研发临床级培养基和支架材料，减少批次间差异； 6 建立类器官生物库，为临床应用提供稳定的细胞来源。 举办地点 ：上海 论坛规模 ： 50 余授课嘉宾， 800 余参会嘉宾 主办单位 ：上海傲顺医药、上海佰傲泰医药科技、药 ...

Core Viewpoint - The Ministry of Science and Technology has released the "Ethical Guidelines for Human Organoid Research," which outlines the ethical principles and requirements for conducting research on human-derived organoids, emphasizing the need for strict operational norms and ethical boundaries in sensitive research areas [1][2]. Group 1: Ethical Guidelines Overview - The guidelines were developed by the National Science and Technology Ethics Committee's Life Sciences Ethics Subcommittee, focusing on ethically sensitive research types such as brain organoids and human stem cell embryo models [1][2]. - The guidelines aim to establish a comprehensive ethical governance framework that covers the entire research process, ensuring scientific goals are clear and ethical norms guide innovation without hindering research [2][3]. Group 2: Specific Requirements - The guidelines require that organoid research must have clear scientific objectives, sufficient scientific basis, and verifiable scientific value, while ensuring ethical compliance throughout all research phases [2][3]. - For brain organoid research, there is a particular emphasis on monitoring the development of complex neural networks and spontaneous electrical activity, with a focus on potential consciousness attributes [2][3]. Group 3: Restrictions and Monitoring - The guidelines impose restrictions on the cultivation time of stem cell embryo models, enhance process monitoring, and clearly define prohibited actions to prevent ethical breaches [3]. - It is explicitly prohibited to implant stem cell embryo models into human or non-human animal uteri, maintaining strict adherence to ethical boundaries [3].

以下文章来源于信风TradeWind ，作者郑敏芳 信风TradeWind . 关注资本市场的趋势与发展 恒河猴、小鼠等实验动物长期以来是新药研发的"无名英雄"，它们用自己的身体为人类药物安全保驾护航。 随着监管部门相关政策的出炉，这一切正在悄然发生变化。 4月24日，工业和信息化部等七部门关于印发《医药工业数智化转型实施方案（2025—2030年）》，提炼了41个关于技术创新发展的典型场景，为医药企业数 智化转型提供参考。 其中提到" 动物模型数据挖掘与虚拟动物实验 "，即针对动物替代需求高、与人体结果一致性有偏差等问题，可以运用数据挖掘、模拟技术，建立动物造模计算 机仿真模型。 更大变化则来自14天前的大洋彼岸。 4月10日，FDA发布《减少临床前安全性研究中动物实验的路线图》（下称"路线图"），指出 将逐步取消单克隆抗体（单抗）及其他药物的临床前安全性研究 中动物实验，转而采用类器官等更多新的替代技术。 这场变革，正在重塑中国医药行业的游戏规则。 为此，信风走访调研多家CXO、模式动物企业、AI制药企业、类器官相关企业后发现，此次动物实验冲击波或将带来多重变化： 一是短期内影响有限，长期则是行业发展方向 ...